PNNL to receive NIH contract for proteomic studies of potential therapeutic targets
Researchers at Pacific Northwest National Laboratory have learned they will be awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID) to identify proteins that can be used as targets for drug therapy. Specifically, the team will use the high-throughput proteomics technologies developed at PNNL to characterize the proteome of Salmonella typhimurium and orthopox virus to identify proteins required for productive infections.
The 5-year, $10.3M project will involve collaborators from the Oregon Health Sciences University, where the pathogen work will take place. The key PNNL staff are Dick Smith, Karin Rodland, Mary Lipton, David Camp, Yufeng Shen, Ljiljana Pasa-Tolic, Christophe Masselon, Gordon Anderson, Joshua Adkins, Ron Moore, and members of the entire Environmental Molecular Sciences Laboratory high-throughput proteomics team.
The proposal was written for RFP-NIH-NIAID-DMID-BAA-03-08, Biodefense Proteomics Research Programs: Identifying Targets for Therapeutic Interventions using Proteomic Technology. The NIAID, which is one of the National Institutes of Health, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.